Tag: Lord Hunt of Kings Heath

The below Parliamentary question was asked by Lord Hunt of Kings Heath on 2015-11-23.

To ask Her Majesty’s Government whether the running costs of existing and future fluoridation schemes will continue to be funded when the ring-fenced public health grant is removed; and if so, how.

Lord Prior of Brampton

Since April 2013 Public Health England (PHE), on behalf of the Secretary of State, has recovered the operational costs of water fluoridation from local authorities served by these arrangements. The Secretary of State is required to meet the reasonable fluoridation capital and operating costs incurred by water undertakers in England and has the power to require local authorities to make payments to the Secretary of State to meet any such costs he has incurred. There are no proposed changes to the legislation affecting these arrangements.

Funding arrangements for the capital costs of new fluoridation schemes in England will need to be agreed between local authorities and PHE, on behalf of the Secretary of State, as part of the preparatory work before the scheme can commence.

The below Parliamentary question was asked by Lord Hunt of Kings Heath on 2015-12-15.

To ask Her Majesty’s Government what is the current membership of the care.data Advisory Group.

Lord Prior of Brampton

The care.data Advisory Group met between March 2014 and October 2015 and has now been disbanded. The group was Chaired by Ciarán Devane, who at the time was a non-executive director of NHS England, and included representatives from the following organisations:

– Academy of Medical Royal Colleges;

– Association of Medical Research Charities;

– Big Brother Watch;

– British Heart Foundation;

– British Medical Association;

– HealthWatch England;

– Hurley Group;

– Kings College London;

– Kings Fund;

– medConfidential;

– MIND;

– National Institute for Health Research;

– National Voices;

– Patients4Data;

– Royal College of General Practitioners;

– Royal College of Psychiatrists;

– Clinical Commissioning Groups;

– UCL Partners; and

– Wellcome Trust.

The below Parliamentary question was asked by Lord Hunt of Kings Heath on 2015-12-21.

To ask Her Majesty’s Government what is their assessment of the risk of a conflict of interest when members of the Association of Pharmaceutical Specials Manufacturers both provide the reference prices from which to set the NHS tariff prices for specials in the primary care sector and supply those specials to community pharmacists.

Lord Prior of Brampton

Members of the Association of Pharmaceutical Specials Manufacturers do not provide the Department with reference price data for their products. Individual manufacturers provide data on their sales volumes and selling prices to the Department under a memorandum of understanding between manufacturers and the Department. This data is then used to set a reimbursement price which reflects the price at which community pharmacies purchased these products in the quarter before.

The below Parliamentary question was asked by Lord Hunt of Kings Heath on 2016-01-18.

To ask Her Majesty’s Government whether, as a result of the review of the NHS Commissioning Board’s policy on the autonomy of Commissioning Support Units (CSUs), CSUs that want to become staff enterprises or staff mutuals will have access to working capital on the same basis as other options open to CSUs.

Lord Prior of Brampton

It will be for NHS England’s Commissioning Committee to decide, in due course, whether to offer Clinical Support Units (CSUs) who apply to become autonomous, access to working capital and if so, on what terms.

The below Parliamentary question was asked by Lord Hunt of Kings Heath on 2016-01-25.

To ask Her Majesty’s Government, further to the Written Answer by Lord Prior of Brampton on 19 January (HL4840), why the independent review of the contract between Cambridgeshire and Peterborough Clinical Commissioning Group and UnitingCare Partnership will only focus on the commissioner perspective.

Lord Prior of Brampton

We are advised that NHS England’s review of the contract between Cambridgeshire and Peterborough Clinical Commissioning Group and UnitingCare Partnership will focus on the commissioner perspective. Monitor, as the sector regulator for health services in England, will also be conducting a review.

However, Monitor’s review will assess the contract from the perspective of the providers involved and consider how relevant issues might be mitigated in the future. Monitor and NHS England will share their respective findings with each other.

The below Parliamentary question was asked by Lord Hunt of Kings Heath on 2016-02-09.

To ask Her Majesty’s Government what assessment they have made of the experience that Bain and Company has to assess evidence to support transformation and potential for replication in terms of health services in the NHS context.

Lord Prior of Brampton

The Healthcare Financial Management Association (HFMA) commissioned Bain and Company to support vanguards as an extension to work previously commissioned from the company as part of a programme called Future Focused Finance, an initiative sponsored by the Department of Health and arm’s length bodies. This earlier work for the HFMA had focused on the design of a value-based decision effectiveness tool, piloted in Mid-Cheshire and Liverpool. The HFMA, in partnership with NHS England, commissioned the extension to this work so that the tool could be used to support value-based decision-making in the 2016-17 New Care Models programme.

Alternatives were not sought from competitors because the vanguard support built on the original Bain and Company work for the HFMA.

The value of the vanguard support contract is £650,000. Value for money was obtained by negotiation, having been benchmarked with other commissions made by the National Health Service to external health consultancies.

As part of the contract, Bain and Company will be handing over its approach to NHS England, so that NHS England can support other areas in implementing new care models.

Bain and Company has not been commissioned to assess evidence to support transformation and potential for replication of new care models in other areas. The company is commissioned to develop and implement a framework that appropriately experienced NHS staff can use to assess such evidence. Intellectual property rights in respect of the framework in the future are assigned to HFMA under the terms of the contract. The NHS is entitled to use the framework free of charge in perpetuity.

Bain and Company is involved in the development of the tool used to make the assessment, and in the implementation of the process to use that tool. The company is specifically commissioned to help vanguard sites to use the tool and to summarise the resulting value propositions to facilitate decision-making by NHS England.

No conflict of interest arises as decisions concerning funding allocations for individual vanguards are made by NHS England’s Executive Team and Investment Committee and not Bain and Company.

The below Parliamentary question was asked by Lord Hunt of Kings Heath on 2016-02-23.

To ask Her Majesty’s Government, of all the schools that have had their admission arrangements objected to in (1) 2014, and (2) 2015, what percentage were found not to have violated the School Admissions Code at least once.

Lord Nash

In 2013/14, the percentage of objections referred to the adjudicator which were not upheld was 14%. In 2014/15, the percentage was 20%.

The below Parliamentary question was asked by Lord Hunt of Kings Heath on 2016-03-01.

To ask Her Majesty’s Government, further to the Written Answer by Lord Prior of Brampton on 4 January (HL4800), what evidence they have that suggests that the complexity of choice in wound dressings for nurses and clinicians makes their clinical decisions more difficult and can lead to over-specification and variation in standards of care.

Lord Prior of Brampton

The NHS Catalogue contained over 600,000 products, many of which had been not used in excess of the last 12 months or were seemingly duplicate items. Given the sheer volume of products, this creates the complexity faced by clinicians and nurses when determining the appropriate products to use, which directly makes their decisions more difficult.

By undertaking the planned clinical rationalisation of the products available via NHS Supply Chain, the Department aims to reduce this complexity, removing unnecessary products, ensuring that those available to the National Health Service are of an appropriate specification in order to maintain high standards of patient care.

The clinical rationalisation work is being undertaken by practising clinicians taking into account feedback from the National Institute for Health and Care Excellence and other relevant programmes, such as ‘ Getting it Right First Time’.

The below Parliamentary question was asked by Lord Hunt of Kings Heath on 2016-03-16.

To ask Her Majesty’s Government whether they support NHS England’s decision to penalise providers for treating patients when numbers breach levels designated for Operational Delivery Networks, even if that treatment is in accordance with NICE guidance.

Lord Prior of Brampton

NHS England is operationally independent, and it is for them to determine how best to deliver the objectives in the mandate to NHS England, as well as ensuring the best use of resources available to it.

The National Institute for Health and Care Excellence (NICE) specifically requires Operational Delivery Networks (ODNs) to prioritise hepatitis C patients on the basis of clinical need, as part of a progressive rollout of treatments over the next five years.

NHS England is funding providers to treat patients at the rate outlined in NICE’s guidance, apportioned to local ODNs based on local health needs. NHS England has invested in a Commissioning for Quality and Innovation scheme to incentivise ODNs to meet their agreed rate of roll-out. If their treatment rates deviate from this agreed rate of treatment, they are no longer eligible for these incentives.

The below Parliamentary question was asked by Lord Hunt of Kings Heath on 2016-04-13.

To ask Her Majesty’s Government how many employees of (1) NHS England, and (2) Arden GEM Commissioning Support Unit, were seconded to the Special Projects Team in (a) 2014, and (b) 2015, and how many are currently seconded from each.

Lord Prior of Brampton

The Special Projects Team (SPT) is a service hosted by Arden and GEM Commissioning Support Unit (CSU). In 2014 and 2015 the team had two full-time employees, one employed by NHS England, and then seconded to the CSU to work directly on SPT issues, and one person employed by the CSU (through the NHS Business Services Authority) working directly on SPT matters. This position continues at present.